EVOTEC EXPANDS SCREENING CAPACITY AT HAMBURG HEADQUARTERS THROUGH EFRE/REACT-EU GRANT

- EXPANSION OF SCREENING CAPACITIES AND SAFETY PHARMACOLOGY AT THE COMPANY’S HEADQUARTERS
- FOCUS ON COVID-19 DRUGS AND RESEARCH IN VIRAL DISEASES
- CITY OF HAMBURG SUPPORTS EXPANSION WITH € 4 M FROM THE EUROPEAN REGIONAL DEVELOPMENT FUND (“ERDF”) UNDER THE REACT-EU PROGRAMME

Hamburg, Germany, 30 March 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that there will be two new high-throughput screening (“HTS”) facilities at the Company’s headquarters in Hamburg, as well as additional equipment for investigating the safety and efficacy of new therapeutic candidates. The research focus is on COVID-19 therapeutics and other viral diseases.

The City of Hamburg supports the expansion with € 4 m from the European Regional Development Fund ("ERDF") under the REACT-EU (Recovery Assistance for Cohesion and the Territories of Europe) programme. The purpose of REACT-EU is crisis relief in the context of the COVID-19 pandemic. The IFB Hamburg (Hamburgische Investitions- und Förderbank) approved the grant to establish the research facility in early 2022.

Evotec will use the new facilities, for instance, to accelerate the research and development of therapeutics against COVID-19. The Company is working on this independently as well as in collaborations with international and regional partners. Moreover, the facilities will be used for projects of the global network initiative PRROTECT (Pandemic Preparedness and Rapid RespOnse TEChnology plaTform) that aims at the collaborative research and development of therapeutics against viruses with a high pandemic risk.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “We are very pleased to have been awarded this ERDF/REACT-EU grant by the City of Hamburg through the IFB Hamburg. The funding will strengthen Hamburg as a research site and contribute to the response to the COVID-19 pandemic. With our
expanded HTS facilities and the additional equipment, we can enter into even more partnerships, especially with smaller companies, and thus support the research and development of new therapeutics even more efficiently.”

**Michael Westhagemann, Senator for Economic Affairs in Hamburg, said:**
“Evotec is an important biotech company. We are proud that Evotec is growing in Hamburg. The ERDF/REACT-EU funding now helps to accelerate research and development of drugs for the treatment of Covid-19 from our city.”

**Christine Freitag, Head of EU Funding at IFB Hamburg, added:** “With the expansion of Evotec’s research facilities, the European ERDF/REACT EU funding enables accelerated drug development to address the current pandemic situation, and helps us to be better prepared for possible future pandemics. In addition, new highly qualified jobs will be created in Hamburg thanks to the funding.”

**About High-Throughput Screening**
High-throughput screening (HTS) is a technology for the discovery of new therapeutics. Many substances are screened in the HTS system for their interaction with specific target structures. The interaction is intended to achieve a specific therapeutic effect. The automation of screening makes it possible to screen substance libraries with several million so-called “compounds” within a few days. The technology is based on the research of Evotec co-founder Prof. Dr Manfred Eigen and mimics evolution in nature, in which (almost) all possible combinations are tried out - and the successful compounds eventually prevail. "Evolutionary technology" also gave its name to Evotec, which launched the first high-throughput screening system miniaturised to microlitres in 2000.

**About PRROTECT**
To prepare for future pandemics, Evotec has initiated the global network initiative PRROTECT (pandemic Preparedness and Rapid RespOnse TEChnology plaTform). PRROTECT builds on Evotec’s existing portfolio of antiviral therapeutics and leverages the Company’s platform to further expand the existing multimodal viral threat pipeline while accelerating the timelines for discovery and development of neutralising antibodies and building a flexible manufacturing network to rapidly deliver such therapeutics in the event of a future pandemic.
multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,000 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.

FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.